HIV-facial Lipoatrophy Clinical Trial
Official title:
Artefill for the Treatment of HIV-associated Facial Lipoatrophy
| Verified date | July 2020 |
| Source | AIDS Research and Treatment Center of the Treasure Coast |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Artefill is an injectable facial filler device that is currently approved by the FDA for the correction of nasolabial folds. This study seeks to examine the use of Artefill in the treatment of HIV associated facial lipoatrophy. Facial lipoatrophy (facial fat loss) related to HIV is a stigmatizing condition characterized by loss of facial fat, most notably in the cheeks and temples.
| Status | Completed |
| Enrollment | 31 |
| Est. completion date | November 2019 |
| Est. primary completion date | November 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: 1. Subject is male or female between 18-80 years of age inclusive at the time of signing the informed consent. 2. Subject desires treatment for facial volume loss. 3. Subject has HIV infection with moderated to severe facial lipoatrophy based on the Modified James Scale grades II-IV. 4. Subject has viral load <400 copies/mL. 5. Subject has CD4 lymphocyte counts >200/mm. 6. Subject has documented negative Artefill skin test or has received treatment with Artefill in the past without evidence of hypersensitivity reaction. 7. Subject is willing to withhold additional aesthetic implant therapies (eg, other soft tissue fillers such as Restylane, silicone, Radiesse, Sculptra or implants such as Gortex, Silastic, etc) for the duration of the study. Exclusion Criteria: 1. Subject has any skin pathology, inflammatory skin disease, or condition that could interfere with the evaluation of the treatment areas. 2. Subject has a history of systemic granulomatous diseases (sarcoid, Wegeners, etc) or connective tissue disease (lupus, dermatomyositis, ect) 3. Subject has history of keloid formation or hypertrophic scarring. 4. Subject has a history of malignancy (other than skin cancer) within 12 months of enrollment. 5.Subject has been treated with systemic corticosteroids(eg, prednisone) or interferon within 1 month prior to study enrollment 6. Subject has thrombocytopenia or a bleeding diathesis. 7. Subject is pregnant, planning to become pregnant, or breastfeeding. 8..Subject has been treated with any of the following within the time intervals specified prior to start of their participation in the study: Bovine collagen-6 months Hyaluronic acid-6 months Calcium hydroxylapatite-6 months Polyacrylamide-at any time Polylactic acid- 6 months Permanent implant grafts at any time. 9. Subject has severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies. 10. Subject has a known hypersensitivity to lidocaine. 11. Subject has a history of allergies to any bovine collagen products. 12. Subject is undergoing or planning to undergo desensitization injections to meat products. 13. Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. 14. Subject has substance abuse, depression, or other issues that, according to the investigator's judgment, would interfere with conduct of the study. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Whole Family Health Center | Vero Beach | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Gerald Pierone, Jr. M.D. | Suneva Medical, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Artefill for the Treatment of HIV-Associated Facial Lipoatrophy | To evaluate the effectiveness of Artefill injections as a long-term treatment for human immunodeficiency virus (HIV)-associated facial lipoatrophy over 36 months by assessing changes in the Global Aesthetic Improvement Scale (GAIS) based on pre/post intervention photography. | 36 months | |
| Primary | Artefill for the Treatment of HIV-associated Facial Lipoatrophy | To evaluate the safety of Artefill injections as a long-term treatment for HIV-associated facial lipoatrophy over 36 months by monitoring the incidence of adverse events. | 36 months | |
| Secondary | Artefill for the Treatment of HIV-Associated Facial Lipoatrophy | To evaluate the effectiveness of Artefill injections as a long-term treatment for HIV-associated facial lipoatrophy over 36 months by assessing changes in the Modified James Scale grade based on assessment of pre/post intervention photography by 2 blinded physicians. | 36 months | |
| Secondary | Artefill for the Treatment of HIV-associated Facial Lipoatrophy | To evaluate the effects of Artefill injections on HIV-associated facial lipoatrophy as evidenced by the subject satisfaction questionnaire. | 36 months | |
| Secondary | Artefill for the Treatment of HIV-associated Facial Lipoatrophy | To evaluate the effects of Artefill injections on the subject's psychological well-being using the Medical Outcomes study-HIV (MOS-HIV)assessment. | 36 months | |
| Secondary | Artefill for the Treatment of HIV-associated Facial Lipoatrophy | To evaluate the acceptability and tolerability of Artefill injections as reported by subjects. | 36 months |